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Ferric ion binding proteins (Fbps) transport Fe
III across the periplasm and are vital for the virulence of many Gram negative
bacteria. Iron(III) is tightly bound in a hinged binding cleft with octahedral coordination geometry involving binding to protein
side chains (including tyrosinate residues) together with a synergistic anion such as phosphate. Niobium compounds are of
interest for their potential biological activity, which has been little explored. We have studied the binding of cyclopentadienyl
and nitrilotriacetato Nb
V complexes to the Fbp from Neisseria gonorrhoeae by UV-vis spectroscopy, chromatography, ICP-OES,
mass spectrometry, and Nb K-edge X-ray absorption spectroscopy. These data suggest that Nb
V binds strongly to Fbp and that a
dinuclear Nb
V centre can be readily accommodated in the interdomain binding cleft. The possibility of designing niobium-based
antibiotics which block iron uptake by pathogenic bacteria is discussed.
1.Introduction
Followingthetherapeuticsuccessofcisplatin,alargenumber
of complexes of other metals have been studied. Nonplat-
inum complexes are of particular interest since they may
display a lack of cross-resistance with cisplatin, bringing
signiﬁcant beneﬁts for chemotherapy. Metallocene dihalides
and pseudohalides of general formula [Cp2MX2]( M= Ti,
V, Nb, Mo; X = F, Cl, Br, I, CN, SCN; Figure 1(a)), have
attracted signiﬁcant interest since they have shown activity
towards a wide variety of murine and human tumors [1–9].
Titanocenedichloride[Cp2TiCl2]wastheﬁrstnon-platinum
metal complex to enter clinical trials but was eventually
abandoned owing to its high reactivity in aqueous solution
which gives rise to formulation diﬃculties [10, 11].
Vanadocene-, molybdenocene-, and niobocene dichlo-
rides also exhibit good activities. Niobocene dichloride
(Cp2NbCl2) is an extremely potent cancerostatic agent
against the Ehrich ascites tumour in CFI mice [12, 13].
Oxidation to Nb
V reduces the tumor inhibiting properties
[14] but potentially could also reduce toxic eﬀects. Hence
there is interest in further investigation of the biological
chemistry of niobium complexes [15].
Iron is the single most important micronutrient for
bacterial survival; it plays important roles in both pathogen
virulence and host antimicrobial resistance [16–18]. Numer-
ous pathogenic bacteria such as Neisseria gonorrhoeae and
Haemophilus inﬂuenzae have evolved a speciﬁc protein-
dependent iron-uptake system which can obtain iron from
the host transferrin (Tf) and lactoferrin (Lf). The three-
component system is a member of the ABC-transporter
super-family (FbpABC) and critical for iron uptake is a ferric
ion-binding protein (FbpA, referred to here as Fbp, a single-
chain34kDaprotein)whichshuttlesFeIII acrosstheperiplas-
micspace,transportingFeIII fromtheoutermembranetothe
cytoplasmic membrane [19]. This essentiality for virulence
makes Fbp an ideal drug target and provides a basis for
the design of novel metal-based antibiotics which combat
resistance to widely used organic antibiotics.
Structural analysis of the FeIII binding site in Fbp
from various bacteria has shown several diﬀerent classes
(Figure 1(b) shows the best characterised). All have a pair
of highly conserved Tyr residues in the active site and
the other metal binding residues are composed of amino
acid side chains (glutamate and histidine) and anions (e.g.,
phosphate). These tyrosines are critical for strong metal2 Bioinorganic Chemistry and Applications
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Figure 1: (a) Metallocene dihalides with antitumor activity. Key: (M) = maximum activity; M = sporadic activity; M = no activity. (b) Fe
III
binding sites in bacterial ferric ion-binding proteins (Neisseria gonorrhoeae or Haemophilus inﬂuenzae).
ion binding, as conﬁrmed by site-directed mutagenesis and
crystal structures of reconstituted Fbp protein complexes
with FeIII. These bacterial Fbps display an extremely high
aﬃnity for ferric iron (KD ∼ 1 × 10
−20 M) but they also
have the capacity to bind other metals. We discovered that
N. gonorrhoeae Fbp could bind Ti, Zr
IV,o rH f
IV in the metal
binding cleft [20–22]. Moreover, besides binding a single
metal ion we observed various metal clusters bound in an
adaptable active site which appears to be able to accommo-
dateawiderangeofmetalsionsandanions.Tofurtherprobe
the speciﬁcity of this site we report for the ﬁrst time studies
of the binding of Nb
V complexes to Fbp, using a wide variety
of techniques including UV-visible spectroscopy, inductively
coupled plasma atomic emission spectroscopy (ICP-AES),
electrospray mass spectrometry, and EXAFS. These studies
are important not only for exploring a potential mechanism
for niobium transport but also as a basis for the possible
design of novel metalloantibiotics.
2. Experimental/MaterialsandMethods
2.1. Materials. [Cp2NbCl2]( A r c o s ) ,m o n o s o d i u mc i t r a t e
(Aldrich),nitrilotriacetic acid(H3NTA, 99%, Aldrich, N840-
7), NaH2PO4 and Na2HPO4 (BDH), Hepes (Aldrich), Tris
(Aldrich), and cetyltrimethylammonium bromide (CTAB,
Aldrich) were used as received. Atomic absorption stan-
dard solutions of Fe (Aldrich, cat: 30595-2), Nb (1000
ppm, niobium(V) chloride in 4% hydroﬂuo, VWR interna-
tional Ltd. Cat: 1026410100), and P (Aldrich, cat: 20735-7)
were used as supplied.
All other chemicals were reagent grade and used as
provided.
Stock solutions of [FeIII(NTA)2]3− and [Nb
V(NTA)n]
were prepared from iron and niobium atomic absorption
standard solutions and stoichiometric amounts of H3NTA.
ThepHvaluesofthesolutionswereraisedslowlyto ∼5.6and
5.26, respectively, with microliter amounts of NaOH (1M).
The [Cp2Nb(OH)Cl2] stock solution was freshly pre-
pared by sonication of [Cp2NbCl2] (2.9mg, 0.099mmol)
in D2O (0.5mL) until no solid remained (typically 0.5–
1h). As [Cp2NbCl2] is insoluble in water, oxygen was
required [22]t oe ﬀect oxidation to the water-soluble nio-
bium(V) complex [Cp2Nb(OH)Cl2][ 14]. Finally a yellow
solution of [Cp2Nb(OH)Cl2] was obtained. This solution
may also contain other hydrolysed Cp2Nb
V species as
well as small amounts of hydrolysed Nb
IV species such as
[Cp2NbCl(H2O)]+.
ElectrophoresiswascarriedoutusingaBio-RadProteinII
Minigel system (protein) and Invitrogen H5 system (DNA).
GE Healthcare AKTA equipment and columns were used for
chromatographic separations of proteins. Precast SDS-PAGE
gels(10%bis-Tris)werepurchasedfromInvitrogenandused
according to the manufacturer’s instructions.
2.2. Overexpression and Puriﬁcation of Fbp. Fbp was overex-
pressedinE.coliTOP10OneShotorDH5αcells(Invitrogen)
transformed with the plasmid pTrc99A/Fbp/Ng. A single
colony from freshly transformed cells was used to inoculate
5mL of 2YT broth which contained 100μg/mL ampicillin
in a sterile 10mL vial. This culture was shaken overnight
at 310K and used to inoculate 3 liters of 2YT broth with
100μg/mL ampicillin in sterile 500mL ﬂasks. After the
ﬂasks were shaken overnight at 310K, a pink cell pellet was
harvested by centrifugation at 10,000 × gf o r1 5m i n u t e sa t
277K and stored at 253K until use.
Fbp was puriﬁed by a modiﬁcation of the method
reported previously [20, 22, 23]. The pink pellet (∼15g) was
defrostedatroomtemperatureandresuspendedin150mLof
50mM Tris (pH 8.0) containing 2% cetyl trimethylammo-
nium bromide (CTAB), sonicated for 5 minutes (30second
on, 30s oﬀ), followed by stirring slowly overnight at 310K.
The white insoluble material was removed by centrifugation
at 10,000 × g for 15 minutes at 277K. The supernatant
(cell-free extract) was dialysed against 5000mL 10mM Tris
(pH 8.0) at room temperature overnight, followed by the
dialysisforanother3hourstoremoveCTABandthenﬁltered
using Whatman paper (0.2μm, Fisher). The cell-free extract
was applied to a RESOURCE S strong cation exchange
column (6mL, Amersham Biosciences); the column was
equilibrated with 10mM Tris buﬀer (pH 8.0). Unbound
proteins were removed by extensive washing with low salt
buﬀer. The target protein (Fbp) was then eluted with a
linear NaCl gradient of low-to-high salt (0-1MNaCl) over
20 column volumes in 10mM Tris buﬀer. Pink fractions
were collected and were analyzed by SDS-PAGE. Fbp was
desalted by dialysis and concentrated by ultraﬁltration
(10kDa cut-oﬀ, Amicon concentrator). The concentration
of puriﬁed iron-bound, holo-Fbp protein was determinedBioinorganic Chemistry and Applications 3
by UV absorption using ε481 = 2,430M−1 cm−1,o rε280 =
48,900M−1 cm−1[24]
2.3. Preparation of Apo-Fbp. Iron-free, apo-Fbp was pre-
pared by treatment of holo-Fbp solutions with 250mM
sodium citrate (pH 4.5) at room temperature for 5 hours,
followed by elution with 250mM sodium citrate (pH 4.5)
on a PD-10 column (GE Healthcare), so as to give negligible
absorbanceat481nm.Theapo-Fbpwasthenwashed6times
w i t h0 . 1 M K C li naC e n t r i c o nY M - 3 0m i c r o c o n c e n t r a t o r
(Amicon), and the stock solution was stored at 4◦Cb e f o r e
use. apo-Fbp concentration was determined with ε280 =
44,270M−1 cm−1 [24].
2.4. UV-Visible Spectroscopy. All UV experiments were per-
formed with 1cm cuvettes on a computer-controlled Cary
300 spectrometer with temperature control at 298 or 310K.
For kinetic experiments, the time courses for the reactions of
apo-Fbp (10μM) with 2mol equivalent of [Cp2Nb(OH)Cl2]
or [Nb(NTA)2]− were recorded for solutions in Hepes buﬀer
(10mM, pH 7.4) at 310K. UV/Vis spectra were recorded at 5
minutesintervalsagainstthesamebuﬀersolutioncontaining
the same amount of [Cp2Nb(OH)Cl2]o r[ N b ( N T A ) 2]− in
the reference cuvette.
First-order rate constants, kobs, were calculated by ﬁtting
plots of absorbance at 245nm versus time to (1) using the
programOrigin7.5,whereA,A0,andA∞ aretheabsorbances
at time t, time zero, and after inﬁnite time:
log(A∞ −A) =− kobst +log(A∞ −A0). (1)
For titration experiments, solutions were prepared by dilut-
ing aliquots of a stock apo-Fbp solution to ∼10μMw i t h
10mM Hepes buﬀer, 5mM phosphate, pH 7.4. Aliquots of
metal complex (0.5–10μl) were added, and each solution
was allowed to equilibrate at 310K for 1 hour before the
spectrum was recorded.
The displacement of metal ions from the protein was
also monitored by adding aliquots of 1:50 Nb:NTA to
(iron-bound) holo-Fbp in the above buﬀer at 310K. UV-
visiblespectrawererecordedhalfanhouraftereachaddition.
Buﬀers containing the same amount of 1:50 Nb:NTA were
used as references. The binding or release of FeIII was
monitored by the increase or decrease in absorbance at
481nm.
2.5. Chromatographic Analysis. For chromatographic analy-
sis, the Nb-Fbps were prepared by reacting apo Fbp with
20mol equiv of freshly prepared Cp2NbCl2 (bubbled with
air,asoxygenisrequiredtoeﬀectoxidationtothewatersolu-
ble niobium(V) complex Cp2Nb(OH)Cl2)o r[ N b ( N T A ) 2]−
for 48 hours at 310K in 10mM Hepes buﬀer, pH 7.4. Small
molecules (<30kDa) were removed by ultraﬁltration using
0.1MKCl, and then the sample was applied to a Mono
S HR5/5 column equilibrated with Hepes buﬀer (10mM,
pH 7.4, 25mL), followed by gradient elution with 0-1M
KCl in Hepes (10mM; pH7.4) ﬂow rate 0.5mLmin−1.P e a k
fractions were collected and pooled, and then subjected to
ultraﬁltration (Centricon, 30kDa cut oﬀ, YM-30, Millipore)
to remove NaCl.
2.6. ICP-OES Analysis. ICP-OES was performed on Perkin
ElmerOpticalEmissionSpectrometerOptima5300DVusing
standard methods. Metal-loaded proteins were prepared
using the same chromatographic procedures as for holo-
Fbp isolation, collected and puriﬁed by using Centricon 30
(Amicon) ultraﬁltration and washing six times with ultra-
pure water followed by ultraﬁltration after each washing.
The protein solution was ﬁnallydiluted with ultrapure water.
The contents of Nb and S were measured, after digestion
of the samples, using the emission lines of 309.418nm and
181.975nm for Nb and S, respectively.
2.7. Mass Spectrometry. Samples Nb-Fbps for ESI-MS
were prepared by reacting a 20-fold molar excess of
[Cp2Nb(OH)Cl2]o r[ N b
V(NTA)2] with apoFbp (ca.
0.5mM) in 10mM HEPES buﬀer pH 7.5 in a water bath
at 310K for 48 hours. Unbound Nb
V complexes were
removed from the protein by ultraﬁltration (Centricon 30,
cut-oﬀ 30kDa, Amicon) washing with 0.1MKCl and H2O
three times, respectively, and then exchanged into a 10mM
NH4Ac buﬀer (pH 8.0) by using a PD-10 column.
Positive-ion electrospray mass spectrometry was per-
formed on a Micromass Platform II quadruple mass
spectrometer equipped with an electrospray ion source.
The puriﬁed holo-Fbp, apo-Fbp, or recombinant Nb-Fbp
samples in 10mM NH4Ac buﬀer (pH 8.0) were diluted
with CH3CN/H2O (1:1, v/v) to a ﬁnal concentration of
25μM.Eachsamplewasinfusedat50μL/minutedirectlyinto
the mass spectrometer, and the ions were produced in an
atmospheric pressure ionization (API)/ESI ion source. The
spray voltage was 3.50 kV. The cone voltage was varied from
20 to 60 V as required. The capillary temperature was 338K
for direct infusion, with a 450Lh−1 ﬂow of nitrogen drying
gas. The quadrupole analyzer, operated at a background
pressure of 5.9 × 10
−5 mBar, was scanned at 200Das−1 for
direct infusion. Data were collected (for 10 scans during the
directinfusionassays)andanalyzedonaMassLynx(ver.3.5).
The deconvoluted average molecular mass was determined
using the MaxEnt and Transform algorithms of massLynx
software.
2.8. X-Ray Absorption Spectroscopy. X-ray spectra were
recorded at the niobiumK edge on EXAFS station 16.1
at Daresbury Laboratory Synchrotron Radiation Source
(operating at 2GeV) using an Si  220  double crystal
monchromator and vertically focusing mirror for harmonic
rejection. Data for apo-Fbp loaded with Nb
V were collected
at 13K (using a liquid helium cryostat) in ﬂuorescene mode
using a 13-element solid state germanium detector. Data
were collected in k space using a k3-weighted regime for
counting time with a total scan time of 40 minutes. 40
scans were collected from each sample. The edge positions
were calibrated against an Nb foil. Samples were prepared
as follows. Puriﬁed native Fbp was concentrated to 5mM by
ultraﬁltration and washed six times with 0.1MKCl. Nb-Fbp4 Bioinorganic Chemistry and Applications
(1mM) was prepared by reacting apo-Fbp with 10mol eq
of Cp2Nb(OH)Cl2 in Hepes buﬀer (pH 7.4). The excess of
[Cp2Nb(OH)Cl2] was removed from the yellowish solution
by ultraﬁltration, washing three times with 0.1MKCl and
then ultrapure water.
Data were processed using EXCALIB and SPLINE (mod-
iﬁed for use with EXCURV) [25]. The EXAFS data were con-
verted into k space and analyzed using the fast curved wave
(or Rehr-Albers) theory [26] including up to third-order
multiple scattering contributions in EXCURV98 [27]. Phase
shifts were calculated using Hedin-Lundquist exchange and
correlation potentials [28, 29] and tested against the EXAFS
data for [Cp2NbCl2]a n dN b C l 5. All the data analysis was
conducted on raw EXAFS data (without Fourier ﬁltering)
weighted by k3 to compensate for diminishing amplitude at
high k.
3. Results andDiscussion
3.1. Characterization of Fbp. Since Fbp contains an N-
terminal signal sequence that directs Fbp to the periplasmic
space,theoverexpressedproteinwaslocatedintheperiplasm
of E. coli. The molecular masses of holo-Fbp and apo-
Fbp determined by electrosprary mass spectrometry were
33,640Da, in good agreement with the amino acid sequence
(309 amino acids, without iron or phosphate theoretical
mass of 33639.39Da). This suggests that, under the condi-
tions used for mass spectrometry, neither holo-Fbp nor apo-
Fbp had iron or synergistic anion bound to the protein and
that the Fbp signal sequence had been cleaved at Asp23 upon
translocation to the periplasm. The presence of iron in holo-
Fbp was evident from the ligand-to-metal charge-transfer
(LMCT) (tyrosinate-to-FeIII)b a n do fF e III-Fbp (vide infra).
For metal binding experiments, iron was eﬃciently removed
by incubation with excess citrate to generate apo-Fbp with
no detectable iron remaining.
3.2. Rate and Stoichiometry of Nb Binding to ApoFbp. The
time-coursesofreactionsbetweenapoFbpand[Nb
V(NTA) 2]−
(we use this formulation for solutions containing Nb
V
and 2mol equiv of NTA) or [Cp2Nb
V(OH)Cl2]w e r e
studied using UV/Vis spectroscopy. Two molar equivalents
of [Nb
V(NTA)2]− or [Cp2Nb
V(OH)Cl2]w e r ea d d e dt oa
solution of apoFbp (∼10μM, in 500μL1 0m MH e p e sb u ﬀer,
5mMphosphate,pH7.4)at310K.;typicalspectraareshown
in Figures 2 and 3, respectively. In the case of [Nb
V(NTA)2],
the reaction produced a UV diﬀerence spectrum which
is similar to reactions of other metal ions with apoFbp
[20, 30]; two new positive bands appeared at ca. 245 and
295nm, and increased in intensity over a period of 60
minutes (Figures 2(a) and 2(b)). These bands are assignable
to π-π∗ transitions of Tyr residues deprotonated by binding
to Nb
V. Similar bands are seen when both bacterial and
serum transferrins bind to a wide variety of metal ions
[31–33]. This suggests that Nb
V ions can occupy speciﬁc
FeIII binding sites. Best ﬁts to the data were obtained using
ﬁrst-order kinetics equations, although the rate law was
not investigated. The ﬁrst-order rate constant, kobs,w a s
3.03±0.01h−1 (310K), and the extinction coeﬃcient (Δε245)
reached ca. 15200M−1 cm−1(Figure 2(c)).
In the case of [Cp2Nb
V(OH)Cl2], the reaction produced
two new bands in the UV/Vis spectra; one broad band is
centred at around 320nm. The other sharp band is at ca.
244nm (Figure 3(a)). The reaction was complete in ca. 2
hours (Figures 3(a), 3(b) and 3(c)). Kinetic studies revealed
kobs of 1.24 ±0.03h−1 (310K), and the extinction coeﬃcient
(Δε244) reached ca. 16700M−1 cm−1 (Figure 3(d)). These
data indicate that the reactions occur in two kinetic phases;
however, the initial phases of the reactions of apoFbp
with [Nb(NTA)2]− and [Cp2Nb
V(OH)Cl2] were fast (within
1hourand2hours,resp.).
Analysisofthetitration curvesforthereactionofapoFbp
with [Nb(NTA)2]− and [Cp2Nb(OH)Cl2] (Figures 2(d) and
3(e)) suggests that about two Nb
V ions bind strongly to Fbp
in both cases. In these experiments, each sample was allowed
to equilibrate for 2 hours after each addition and then UV
diﬀerence spectra were recorded. The absorptivity Δε244/245
increased linearly with increase in molar ratio r[Nb]/[apoFbp]
until a value of ca. r = 2. Beyond r = 2, the titration
curve reached a plateau (Figures 2(d) and 3(e)). Titration
studies suggested that a niobium:protein molar ratio of 2:1
is suﬃcient to deprotonate both Tyr 195 and Tyr 196 when
phosphate is present as the synergistic anion; phosphate is
known to bind in the interdomain cleft of the apo-protein
and may prepare the cleft for metal entry [34]. Beyond a
2:1 [Nb]:[apoFbp] ratio there was little increase in the
absorption at 244 or 245nm (Figures 2(d) and 3(e)). These
data suggest that the initial reaction with apo-Fbp involves
Nb
V binding to Tyr 195 and Tyr 196 either initially as a
mononuclear niobium centre binding to one of the Tyr
side-chains followed by subsequent binding of the second
niobiumtothesecondTyrandformationofanoxo-niobium
dinuclear center or perhaps by direct uptake of a dinuclear
species which may involve one Nb
V binding to both Tyr
residues or one to each. Hence there is little increase in the
absorption at 241nm beyond a 2:1 [Nb]:[apoFbp] ratio. In
particular, the mobility of Tyr 196 (as observed in crystals
of oxo-FeIII-Fbp) [22] may be important for capturing Nb
V
ions at the protein surface and delivering them into the
binding cleft. In our previous studies of the binding of
trinuclear FeIII,H f
IV (also pentanuclear Hf
IV), and Zr
IV oxo-
clusters to Fbp, we have observed anchoring of these centres
viathesetyrosinateswitheachbindingtodiﬀerentmetals(or
in the case of one FeIII cluster, anchoring via a single Tyr)
[20, 22, 35]. It appears that the other two protein ligands,
His9andGlu57arenotessentialfortheinitialstepsofmetal
binding in vitro.
3.3. Displacement of FeIII from Fe-Fbp by Nb
V. To conﬁrm
that Nb
V binds to the speciﬁc FeIII-binding sites of Fbp/Ng,
we investigated the displacement of FeIII from holo-Fbp
(FeIII-phosphate-Fbp) by Nb
V. Holo-Fbp was saturated with
Fe3+ by incubating apoFbp (100μM) with 10mol equivalent
1:2 Fe:NTA in 10mM Hepes, 5mM phosphate, pH 7.4,
310K for 24 hours. After removing unbound Fe and
diluting the Fe-Fbp solution to 25μM, 1.0mol equivalentBioinorganic Chemistry and Applications 5
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Figure 2: (a) UV diﬀerence UV/Vis spectra recorded at various times during the reaction of apoFbp (10μM) with 2.0mol equivalents of
[Nb(NTA)2]− in 10mM Hepes buﬀer, 5mM phosphate, pH 7.4, 310K. (b) Time course for reactions of apo-Fbp (ca. 10μM) with 2mol
equivalents of [Nb(NTA)2]− in the 10mM Hepes buﬀer, 5mM phosphate, pH 7.4, 310K, as a plot of molar absorptivity versus time for
reaction. (c) Diﬀerence UV/Vis spectra for the titration of apoFbp (10μM) with [Nb(NTA)2]− in 10mM Hepes buﬀer, 5mM phosphate,
pH 7.4, 310K (1h equilibration). Molar ratios of Nb-complexes: apo-Fbp from bottom to top: are 0–2.0 in 0.2mol equivalent steps, then
2.5, 3.0, 3.5, 4.0. (d) Titration curve for the reaction in (C), and Δε is the absorbance at 245nm divided by the Fbp concentration.
of [Nb(NTA)2]− was added to the holo-Fbp solution in
physiological buﬀer at 310K. There was no obvious change
to the LMCT band of FeIII-Fbp at 465nm (Figure 4, insert).
In contrast, with the addition of 1:50 Nb:NTA, this band
decreased in intensity to about half of its original value
at the mol ratio of r[Nb]/[Fe-Fbp] of 10, and to about 21%
when r[Nb]/[Fe-Fbp] is 33 (Figure 4). It can be seen from the
graph that the wavelength of the absorption maximum of
the LMCT band shifted from 480nm to 465nm during
this titration. This suggests that under these conditions
phosphate is displaced form iron [30] and that Nb
V can
compete with FeIII for binding to Fbp, perhaps with initial
formation of mixed-metal oxo-Fe/Nb species in the binding
cleft.
3.4. Displacement of Nb
V from Nb2-Fbp by FeIII. We also
investigated the displacement of Nb
V from Nb-Fbp by FeIII.
Nb-Fbp was prepared by incubating apo-Fbp (100μM) with
10mol equiv equivalent 1:2 Nb:NT A in 10mM Hepes,
5mM phosphate−, pH 7.4, 310K for 24 hours, and FeIII-
binding was monitored by the appearance of the FeIII-Fbp
LMCT band at 465–480nm. Nb-Fbp was titrated with 0.2–
10mol equiv 1: 2 Fe:NTA in the same buﬀer solution at
the same temperature. UV diﬀerence spectra were recorded
0.5 hours after each addition of FeIII. A peak centred at ca.
465nm appeared and increased after 1.2mol equiv of 1:
2 Fe:NTA had been added, at which point it had almost
reached its ﬁnal intensity and no further increase occurred
with 10mol equiv FeIII present (Figure 5). Therefore, under6 Bioinorganic Chemistry and Applications
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Figure 3: (a) Diﬀerence UV/Vis spectra recorded at various times during the reaction of apoFbp (9.8μM) with 2.0mol equivalents of
[Cp2Nb(OH)Cl2]i n1 0m MH e p e sb u ﬀer, 5mM phosphate, pH 7.4 (b) Time course for reactions of apo-Fbp (ca. 9.8μM) with 2mol
equivalents of [Cp2Nb(OH)Cl2]i n1 0m MH e p e sb u ﬀer, 5mM phosphate, pH 7.4, 310K, as a plot of molar absorptivity versus time of
reaction. (c) Time course for reactions of apo-Fbp (ca. 9.8 μM) with 2mol equivalents of [Cp2Nb(OH)Cl2] in the 10mM Hepes buﬀer,
5mM phosphate, pH 7.4 at 310K as a plot of molar absorptivity versus time of reaction. (d) Diﬀerence UV/Vis spectra for the titration of
apoFbp (9.8μM) with [Cp2Nb(OH)Cl2]i n1 0m MH e p e sb u ﬀer, 5mM phosphate, pH 7.4, 310K (2h equilibration). Molar ratios of Nb-
complexes: apo-Fbp from bottom to top: are 0–2.0 in 0.2mol equivalent steps, then 2.5, 3.0, 3.5, 4.0. (e) Titration curve for the reaction in
(D), Δε is the absorbance at 244nm divided by the Fbp concentration.Bioinorganic Chemistry and Applications 7
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the conditions studied here, FeIII can displace Nb
V from the
protein.
3.5. Characterization of Nb-Fbp by Ion Exchange Chromatog-
raphy and ICP-OES Analysis. The products from reaction of
apoFbp with 20molar equiv of freshly prepared [Cp2NbCl2]
(bubbled with air (oxygen) to obtain the water soluble
niobium(V) complex [Cp2Nb(OH)Cl2]) or [Nb(NTA)2]−
are at 310K in Hepes buﬀer (10mM, pH 7.4) for 48
hours. Unbound Nb was removed by extensive ultraﬁltration
and the sample was applied to a cation exchange Mono
S HR5/5 column equilibrated with Hepes (10mM; pH
7.4, 25mL), followed by gradient elution with 0-1MKCl
in Hepes (10mM; pH 7.4) ﬂow rate 0.5mLmin−1.T h e
chromatograms are shown in Figure 6.W eo b s e r v e dt w o
peaks that elute at diﬀerent KCl concentrations which we
assume to be the diﬀerent forms of Nb-Fbp with diﬀerent
charges. It seems likely that the products from these loading
reactions contain diﬀerent multinuclear forms of Nb-Fbp.
Reaction of Fbp with 1 and 20mol equivalents of
[Cp2Nb(OH)Cl2] gave products containing an average of
0.86and2.23molNbpermolprotein,respectively(ICP-OES
data; see Table 1). In the case of reactions with 1 and 20mol
equivalents of [Nb(NTA)2]− under the same conditions,
the products contained ca. 0.91 and 2.41mol Nb per mol
protein.
3.6. Electrospray Ionization Mass Spectroscopy (ESI-MS). The
recombinant protein, prepared as described in experimental
section, was further studied by electrospray ionization mass
spectrometry. The products were investigated as dilute
solutions in 10mM NH4Ac, pH 8.0. For the reaction of
[Cp2Nb(OH)Cl2]withapoFbp,peakscentredatmass34813,
34829, 34842, 34871, and 34890 are tentatively assigned to
[aFbp + 4Cp2NbCl2], [aFbp + 4Cp2NbCl2+O H −], [aFbp
+4 C p 2NbCl2 +2 O H −], [aFbp + 4Cp2NbCl2 +3 O H −],
and[aFbp+4Cp2Nb(OH)Cl2],respectively.Another sample
prepared from apoFbp and [Nb(NTA)2]− gave peaks centred
at mass 34655, 34837, and 34965 corresponding to [aFbp
+N H +
4], [aFbp + 2Nb(NTA)2 +C H 3COO−], [aFbp +
3Nb(NTA)2 +N T A ] .Table 2 contains a list of the species
observed by ESI-MS assays of Nb-Fbp. These results indicate
that apoFbp binds Nb
V tightly under the conditions used
and suggests that the binding cleft can accommodate not
only a single metal ion but also multinuclear Nb species,
as observed previously for iron, zirconium and hafnium.
However, these data alone do not rule out the possible
presence of Nb binding sites elsewhere on the protein and
the formulations require further veriﬁcation before they can
be fully interpreted.
3.7. EXAFS Experiment. To obtain more detailed structural
information, NbK-edge X-ray absorption near-edge struc-
ture (XANES) and extended X-ray absorption ﬁne structure
(EXAFS) studies (Figure 7) were carried out. For these
studies, Nb-Fbp was prepared by treating apo-Fbp with
[Cp2Nb(OH)Cl2] (see experimental section).
The XANES edge position conﬁrms the oxidation state
of the Nb as 5+. The Fourier transform shows two intense,
overlapping peaks at ca. 1.94 ˚ A and 2.12 ˚ A, and a broader
peak at 3.3 ˚ A. The 1.94 ˚ A and 2.12 ˚ A peaks were simulated
with six oxygen atoms as back-scatters at two distances
(2 atoms at 1.94 ˚ A, and 4 atoms at 2.12 ˚ A). These result
from scattering from the atoms directly coordinated to the
Nb
V center and are likely to include tyrosinate, histidine,
glutamate, hydroxide, and oxo groups. ICP measurements
showed that phosphate was not present in this sample (data
notshown).Niobium-aryloxidebondsof1.730–1.985 ˚ Ahave8 Bioinorganic Chemistry and Applications
Table 1: Analysis of the products from reactions of apo-Fbp with [Cp2Nb(OH)Cl2] and [Nb(NTA)2]−.
Reaction mixture(a) Product(b) Reaction mixture Product
[Cp2Nb(OH)Cl2]/[Fbp] [Nb]/[Fbp] [Nb(NTA)2]−/[Fbp] [Nb]/[Fbp]
1:1 0.86 ±0.10:1 1:1 0.91 ±0.10:1
20:1 2.23 ±0.10: 1 20:1 2.41 ±0.10:1
(a) Reactions carried out for 48 hours in 10mM HEPES buﬀer, pH 7.4, 310K.
(a)Fbp concentration determined from A280.
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Figure 6: Characterization of Nbn-FBP (apo-Fbp reloaded with [Cp2Nb(OH)Cl2] (a) or [Nb(NTA)2] (b)) by chromatography on a MonoS
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Table 2: Species detected by ESI-MS assay of products from the
reaction of [Nb(NTA)2]− or [Cp2Nb(OH)Cl2]with apo-Fbp.
Calcd/Da(a) Obsd/Da
Recombinant apo-Fbp with [Cp2Nb(OH)Cl2]
[a-Fbp] (33640) 33648
[aFbp + 4Cp2NbCl2] (34816) 34813
[aFbp + 4Cp2NbCl2+OH−] (34833) 34829
[aFbp + 4Cp2NbCl2+2OH−] (34850) 34842
[aFbp + 4Cp2NbCl2+3OH−] (33867) 34871
[aFbp + 4Cp2Nb(OH)Cl2] (34884) 34890
Recombinant apo-Fbp with [Nb(NTA)2]−
[aFbp + NH+
4] (33657) 33655
[aFbp + 2Nb(NTA)2 +N T A+C H 3COO−] (34835) 34837
[aFbp + 3Nb(NTA)2 + NTA] (34966) 34965
(a)The formulations are merely those which give reasonable ﬁts to the
observed masses and cannot be interpreted as giving structural information
about the nature of the bound complexes. For example some sites could be
on the exposed surface of the protein as well as in the interdomain cleft.
previously been reported, including Nb-Ophenolate distances
of ca. 1.872 ˚ A[ 36]. Thus the two shorter inner-sphere Nb-O
bonds in Nb-Fbp (1.94 ˚ A) are within the range of typical
Nb-O bonds assignable to the Nb-tyrosinate bonds but may
also be due to Nb=O double bonds and a possible bridging
oxo group. The Nb-O bond lengths are also similar to those
in known compounds such as (C2H6NO2)2[NbOF5]a n d
(C 3H8-NO2)2[NbOF 5]·2H2O[ 37], LiNbO(O-2,6-PhMe2)4P·
3THF,LiNbCl3(O-2,6-PhMe2)2P·2THF[38],NbCl3(3-[2,2 -
methylenebis(4,6-di-tert-butylphenol)-5-tert-butylsalicylid-
ene-(2,6-diisopropyl)phenylimine])[34]andthe[(Nb6Cl8O4)
Cl6] cluster. The Nb-Nb peak at 3.3 ˚ A is similar to that
reported for the single Nb neighbor at 3.3 ˚ A in a niobium-
peroxo-citrato complex [39]. The EXAFS data may be
consistent with the presence of a dinuclear Nb-O-Nb centre
in the adduct. No attempt was made to include Cp ligands in
a ﬁt to the EXAFS data.
The EXAFS data do not allow an unambiguous assign-
ment of a structure to the bound niobium(V) dinuclear
centre since only averaged Nb–N/O bond lengths are
obtained and oxygen ligands cannot be distinguished from
nitrogen donors. One possibility is that the dinuclear centre
is anchored to the protein only by coordination to the two
active site Tyr residues, as are the clusters in previously
characterised Fe, Zr, and Hf complexes. The other ligands
for Nb
V may be oxygens from water or hydroxide without
coordination to the His or Glu sidechains which are ligands
in the mononuclear FeIII site.
4. Conclusions
Previous work has shown that eﬃcient iron acquisition is
required for the virulence of pathogenic bacteria and that
Fbp is one of the iron-uptake virulence genes [22, 30, 35, 40–
43]. The di-tyrosyl metal-binding motif in Fbp is highly
conserved and shows a strong binding ability with some
metals. Targetting this protein with an unnatural metal ion
such as niobium(V) which might block iron(III) uptake
therefore becomes a potential strategy for the design of novel
antibiotics.
Since the size of the binding cleft in Fbp is thought to be
matched to FeIII (ionic radius 0.69 ˚ A), previous studies have
shown similar tight binding between apoFbp and various
other metal ions such as Ti
IV (ionic radius 0.75 ˚ A), Zr
IV
(ionic radius 0.86 ˚ A) and Hf
IV (ionic radius 0.85 ˚ A). Hence it
seemed reasonable to suppose that Nb
V (ionic radius 0.78 ˚ A)
might behave in a similar manner to these other metal ions.
As we expected, Nb
V from the [Nb(NTA)2]− and antitumor
complex [Cp2NbCl2]/[Cp2Nb(OH)Cl2] were readily taken
up into the speciﬁc iron sites of ferric iron binding protein.
The tight binding was conﬁrmed by ICP-OES and ESI-
MS studies. Interestingly, kinetic studies showed that the
uptake of Nb
V by apo-Fbp is relatively rapid in vitro under
the conditions used, and titration studies monitored using
UV/visalsoshowthatNb
V canbedisplacedbyFeIII,although
suggesting weaker binding of Nb
V. Structural studies using
EXAFS suggest the presence of a dinuclear Nb(V) centre
possibly with an Nb-O-Nb bridge, but further studies
are needed to deﬁne the conditions under which the Cp
ligands are displaced from Nb on binding to the protein.
These properties may allow Nb
V to bind strongly to Fbp
under certain environmental conditions. It would also be
interestingtoinvestigatepotentialcatalyticpropertiesofsuch
a protein-bound dinuclear niobium centre. The recent novel
use of the metal complex desferrioxamine-gallium (DFO-
Ga) that targets P. aeruginosa iron metabolism and stops
bioﬁlm formation [44], coupled with our work, suggests
that Nb
V complexes should be explored as potential novel
metalloantibiotics.
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